TrialJournal of the European Academy of Dermatology and Venereology : JEADV2021

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.

C Bodemer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.